Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
29.05. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
29.05. | Silexion reports breakthrough in KRAS-driven cancer therapy | 3 | Investing.com | ||
29.05. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers | 191 | GlobeNewswire (Europe) | GRAND CAYMAN, Cayman Islands, May 29, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
21.05. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
21.05. | Silexion Therapeutics Corp: Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer | 169 | GlobeNewswire (Europe) | GRAND CAYMAN, Cayman Islands, May 21, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech company developing RNA interference... ► Artikel lesen | |
14.05. | Silexion Therapeutics GAAP EPS of $0.26 | 1 | Seeking Alpha | ||
13.05. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
13.05. | Silexion Therapeutics Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
13.05. | Silexion Therapeutics Corp: Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | 108 | GlobeNewswire (Europe) | GRAND CAYMAN, Cayman Islands, May 13, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech company developing RNA interference... ► Artikel lesen | |
23.04. | Silexion Therapeutics Stock Surges 52% On Catalent Collaboration For Cancer Therapy | 1 | RTTNews | ||
23.04. | Silexion Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
23.04. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities | 7 | GlobeNewswire (USA) | ||
28.03. | Silexion erweitert Dual-Route-Strategie für KRAS-Krebstherapie | 1 | Investing.com Deutsch | ||
28.03. | Silexion advances dual-route strategy for KRAS cancer therapy | 2 | Investing.com | ||
28.03. | Silexion Therapeutics Corp: Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data | 169 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, March 28, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
28.03. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
27.03. | Silexion Therapeutics Corp - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
18.03. | Silexion Therapeutics Corp - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
18.03. | Silexion Therapeutics GAAP EPS of -$26.36 | 5 | Seeking Alpha | ||
18.03. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 1.022 | GlobeNewswire (Europe) | Grand Cayman, Cayman Islands, March 18, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,70 | +0,06 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CUREVAC | 4,578 | -0,61 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
AMGEN | 239,05 | +0,23 % | ROUNDUP/Aktien New York Schluss: Gewinne - 'Iran-Angriff eine Gesichtswahrung' | NEW YORK (dpa-AFX) - Der Nahost-Krieg hat am Montag die Richtung an den US-Börsen bestimmt. Die wichtigsten US-Indizes legten am Ende kräftig zu und erreichten kurz vor dem Handelsschluss Tageshöchststände.... ► Artikel lesen | |
NOVAVAX | 5,520 | -0,68 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
BIOGEN | 108,05 | -0,37 % | Biogen Inc.: Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results | Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,120 | -11,89 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von... ► Artikel lesen | |
VIKING THERAPEUTICS | 23,925 | -0,60 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 8,378 | +2,20 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 8,322 | +0,87 % | BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report | ||
TEMPUS AI | 58,66 | +0,48 % | Assessing Tempus AI: Insights From 8 Financial Analysts | ||
SAREPTA THERAPEUTICS | 14,660 | -0,34 % | Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny | ||
CARDIOL THERAPEUTICS | 1,240 | -1,74 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,065 | -2,95 % | Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock |